

Table S1. Related to materials and methods. Human and mouse primers for qRT-PCR.

Gene name	Forward primer	Reverse primer
human <i>IRF4</i>	GAGTCACCTGGAATCTTGGC	CCTGCAAGCTCTTTGACACA
human <i>SLC1A1</i> (GLUT1)	GGCATTGATGACTCCAGTGTT	ATGGAGCCCAGCAGCAA
human <i>HK2</i>	AGCCCTTTCTCCATCTCCTT	AACCATGACCAAGTGCAGAA
human <i>MYC</i>	CACCGAGTCGTAGTCGAGGT	TTTCGGGTAGTGAAAACCA
human <i>PPRC1</i>	TGACAAAGCCAGAATCACCC	GTGGTTGGGGAAGTCGAAG
human <i>PGK1</i>	CTTGGGACAGCAGCCTTAAT	CAAGCTGGACGTTAAAGGGA
mouse <i>Slc2a1</i> (GLUT1)	GAGACCAAAGCGTGGTGAGT	GCAGTTCGGCTATAACACTGG
mouse <i>Slc2a3</i> (GLUT3)	ATCGTGGCATAGATCGGTTC	TCTCAGCAGCTCTCTGGGAT
mouse <i>Slc2a6</i> (GLUT6)	GCCCAGGAGGTCATTGAGTA	CCAGCACTACACCTGGACAA
mouse <i>Slc2a8</i> (GLUT8)	GGCATGTAGCACATGAGCAG	GGCATCCTCCTGGCCTAT
mouse <i>Irf4</i>	CAAAGCACAGAGTCACCTGG	TGCAAGCTCTTTGACACACA
mouse <i>Hif1a</i>	AAACTTCAGACTCTTTGCTTCG	CGGCGAGAACGAGAAGAA
mouse <i>Hk2</i>	TGATCGCCTGCTTATTCACGG	AACCGCCTAGAAATCTCCAGA
mouse <i>Gpi</i>	TCAAGCTGCGCGAACTTTTTG	GGTTCTTGGAGTAGTCCACCAG
mouse <i>Pkfl</i>	GGAGGCGAGAACATCAAGCC	CGGCCTTCCCTCGTAGTGA
mouse <i>Aldoa</i>	CGTGTGAATCCCTGCATTGG	CAGCCCCTGGGTAGTTGTC
mouse <i>Pgk1</i>	ATGTCGCTTTCCAACAAGCTG	GCTCCATTGTCCAAGCAGAAT
mouse <i>Pgam1</i>	TCTGTGCAGAAGAGAGCAATCC	CTGTCAGACCGCCATAGTGT
mouse <i>Eno1</i>	TGCGTCCACTGGCATCTAC	CAGAGCAGGCGCAATAGTTTTA
mouse <i>Pkm2</i>	GCCGCCTGGACATTGACTC	CCATGAGAGAAATTCAGCCGAG
mouse <i>Ppargc1a</i> (PGC-1a)	TGAGGACCGCTAGCAAGTTT	TGTAGCGACCAATCGGAAAT
mouse <i>Ppargc1b</i> (PGC-1b)	GAGGTCAAGCTCTGGCAAGT	GCTCTCGTCCTTCTTCTCA
mouse <i>Pprc1</i>	TCTGTCGAGTCTGTTGGAGCA	GGGAATGTCAATGCCTGAGTTT
mouse <i>Gapdh</i>	TTGATGGCAACAATCTCCAC	CGTCCCCTAGACAAAATGGT
mouse <i>18S</i>	CGGCGACGACCCATTGGAAC	GAATCGAACCCCTGATTCCCCGT
mouse mtDNA region 1	TGAACGGCTAAACGAGGGTC	AGCTCCATAGGGTCTTCTCGT
mouse mtDNA region 2	CAGTCCCCTCCCTAGGACTT	ACCCTGGTCCGTTTGTATGTT
mouse mtDNA region 3	TAATCGCACATGGCCTCACA	GAAGTCCTCGGGCCATGATT
mouse gDNA <i>B2m</i>	AGCAAAGAGGCCTAATTGAAGTC	GAAGTAGCCACAGGGTTGGG
mouse gDNA <i>Tuba1a</i>	TGAGGAGGTTGGTGTGGATTC	TGAGGAGGTTGGTGTGGATTC

Figure S1. Related to Fig. 2




Figure S1. Related to Figure 2. Exogenous IL-2 does not rescue proliferation and metabolic reprogramming of *Stim1/2*-deficient CD4⁺ T cells.

(A) Proliferation of CD4⁺ T cells from WT and *Stim1^{fl/fl}Stim2^{fl/fl}Cd4cre* (*Stim1/2^{CD4}*) mice 72 h after anti-CD3/CD28 stimulation with or without 50 U/ml IL-2 and measured by CFSE dilution; representative histograms of 2 repeat experiments.

(B-G) Exogenous IL-2 does not rescue impaired glycolysis and OXPHOS of *Stim1/2^{CD4}* CD4⁺ T cells. Analysis of **(B)** oxygen consumption rate (OCR), **(C)** basal respiration, **(D)** maximal respiration after uncoupling of mitochondria with FCCP, **(E)** extracellular acidification rate (ECAR) and **(F)** basal ECAR of WT and *Stim1/2^{CD4}* CD4⁺ T cells before and 24 h after anti-CD3/CD28 stimulation with or without exogenous IL-2 (50 U/ml) using an extracellular flux analyzer. Means ± SEM of n=3 mice. **(G)** Maximal OCR plotted against ECAR from data shown in (D and F).

Figure S2. Related to Fig. 2





Figure S2. Related to Figure 2. SOCE and calcineurin control abundance of glycolytic and TCA cycle intermediates and nucleotides in activated T cells.

(A) Pathway diagram of glycolysis, the tricarboxylic acid (TCA) cycle and the synthesis of nucleotides and amino acids in T cells.

(B-D) Liquid chromatography/mass spectrometry (LC/MS) analysis of polar metabolites derived from glucose. Non-normalized abundance of metabolites of the **(B)** glycolytic pathway, **(C)** intermediates of the TCA cycle and **(D)** nucleotides in T cells from WT and *Stim1^{fl/fl}Stim2^{fl/fl}Cd4cre* (*Stim1/2^{CD4}*) mice before and 36 h after anti-CD3/CD28 stimulation in the presence or absence of 1 μ M FK506. Metabolite measurements of 3 WT and 4 *Stim1/2^{CD4}* mice per cohort; bar graphs are non-normalized mean \pm SEM.


Figure S3. Related to Fig. 2

A



C

■ WT
□ *Stim1/2^{CD4}*



B




Figure S3. Related to Figure 2. SOCE and calcineurin control amino acid concentrations in activated T cells.

(A) Pathway diagram of glycolysis, the tricarboxylic acid (TCA) cycle and the synthesis of nucleotides and amino acids in T cells.

(B and C) Liquid chromatography/mass spectrometry (LC/MS) analysis of **(B)** non-essential and **(C)** essential amino acids in CD4⁺ T cells from WT and *Stim1^{fl/fl}Stim2^{fl/fl}Cd4cre* (*Stim1/2^{CD4}*) mice before and 36 h after anti-CD3/CD28 stimulation in the presence or absence of 1 μM FK506. Metabolite measurements of 3 WT and 4 *Stim1/2^{CD4}* individual mice per cohort; bar graphs are non-normalized mean ± SEM.

Figure S4. Related to Fig. 3 and Fig. 4




Figure S4. Related to Figure 3 and Figure 4. SOCE controls glucose utilization and expression of glucose transporters, glycolytic enzymes and regulatory factors in T cells.

(A) Glucose utilization from the extracellular medium by CD4⁺ T cells from WT and *Stim1^{fl/fl}Stim2^{fl/fl}Cd4cre* (*Stim1/2^{CD4}*) mice before and 48 h after anti-CD3/CD28 stimulation in the presence or absence of 1 μM FK506. Means ± SEM of 9 mice per group.

(B) Uptake of the tritiated (³H) glucose analogue 2-DG in WT and *Stim1/2^{CD4}* T cells before and 48 h after anti-CD3/CD28 stimulation in the presence or absence of 1 μM FK506. ³H c.p.m. values were normalized to cell numbers; means ± SEM of 3 mice per group.

(C) Analysis of *Slc2a1* (GLUT1), *Slc2a3* (GLUT3), *Slc2a6* (GLUT6) and *Slc2a8* (GLUT8) gene expression in WT CD4⁺ T cells by qRT-PCR 24 h after anti-CD3/CD28 stimulation. Bar graphs are mean ± SEM of 3 individual mice.

(D-G) SOCE controls the expression of transcriptional regulators of glycolysis, glucose transporters and glycolytic enzymes in T cells. Analysis of **(D)** *Myc* and *Irf4*, **(E)** *Slc2a1* (GLUT1) and *Slc2a3* (GLUT3), **(F)** *Hk2*, *Aldoa* and *Pgk1*, and **(G)** *Il2* gene expression in WT and *Stim1/2^{CD4}* CD4⁺ T cells over the course of 72 h after anti-CD3/CD28 stimulation. Means ± SEM of 3 mice.

(H) Analysis of *Ppargc1a* (PGC-1α), *Ppargc1b* (PGC-1β) and *Pprc1* (PPRC1) gene expression in WT and *Stim1/2^{CD4}* CD4⁺ T cells by qRT-PCR 36 h after anti-CD3/CD28 stimulation. Bar graphs are mean ± SEM of 3 individual mice.

Figure S5. Related to Fig. 5




Figure S5. Related to Figure 5. NFAT, IRF4 and c-Myc contribute to the metabolic reprogramming of T cells.

(A) *In silico* analyses of NFATc1 and NFATc2 binding to *Hif1a*, *Myc*, *Slc2a1* (GLUT1) and *Hk2* genes in naive and activated CD8⁺ T cells. Regulatory elements were identified by DNase I hypersensitivity site analysis (Bevington et al. 2016) and accessible chromatin regions were defined by ATAC sequencing (Mognol et al. 2017). NFATc1 (Klein-Hessling et al. 2017) and NFATc2 (Martinez et al. 2015) binding to promoters and regulatory elements was identified by the model-based analysis of CHIP-seq (MACS) method. NFATc1 and NFATc2 binding peaks considered significant by MACS are indicated by blue and orange asterisks, respectively.

(B) Analysis of *Myc* and *Slc2a1* (GLUT1) gene expression in CD4⁺ T cells from WT and *Nfatc1^{fl/fl}Nfatc2^{-/-}Cd4cre* mice before and 36 h after anti-CD3/CD28 stimulation in the presence or absence of 1 μM FK506 by qRT-PCR; means ± SEM of 3 mice.

(C) *Myc* and *Slc2a1* (GLUT1) gene expression in CD4⁺ T cells from WT and *Rosa26^{LSL-caNfatc1} dLckcre (caNfatc1^{Ki})* mice that express a constitutively active form of NFATc1/A (caNFATc1) as described in (B); means ± SEM of 4 mice.

(D) Analysis of *Slc2a1* (GLUT1) gene expression in CD4⁺ T cells from WT SMARTA and *Stim1^{fl/fl}Stim2^{fl/fl}Cd4cre (Stim1/2^{CD4})* SMARTA mice 2 days after retroviral transduction with GLUT1 (before transfer into congenic host mice); means ± SEM of 3-4 mice (see also Figure 5G-H).

(E) Analysis of glucose uptake using the fluorescent glucose analogue 2-NBDG in CD4⁺ T cells from WT and *Stim1/2^{CD4}* SMARTA mice after retroviral transduction with GLUT1, transfer into CD45.2⁺ host mice and LCMV infection on day 8 post-infection; means ± SEM of 3-4 mice (see also Figure 5G-H).

(F-H) Retroviral transduction of CD45.1⁺CD4⁺ T cells from WT SMARTA or *Stim1/2^{CD4}* SMARTA mice with IRF4 or c-Myc *in vitro* followed by adoptive transfer into congenic CD45.2⁺ WT host mice. Host mice were infected with LCMV and donor T cell expansion was analyzed 8 d later.

(G) Representative flow cytometry plots of adoptively transferred donor CD4⁺ CD45.1⁺ Vα2 TCR⁺ T cells from WT SMARTA and *Stim1/2^{CD4}* SMARTA mice; bar graphs show frequencies of cells in spleen 8 days post-infection. Means ± SEM of 5 host mice.

(H) Absolute numbers of CD4⁺ CD45.1⁺ Vα2 TCR⁺ donor T cells in spleen. Means ± SEM of 5 host mice.

Figure S6. Related to Fig. 6 and Fig. 7






Figure S6. Related to Figures 6 and Figure 7. SOCE-dependent and -independent regulation of glycolysis by TCR stimulation and cytokines in T cells.

(A) IL-2 and IL-7 together, but not individually, restore expression of glycolysis-related genes in *Stim1/2*-deficient T cells. qRT-PCR analysis of *Slc2a1* (GLUT1), *Hk2*, *Myc* and *Irf4* gene expression in CD4⁺ T cells from WT and *Stim1^{fl/fl}Stim2^{fl/fl}Cd4cre* (*Stim1/2^{CD4}*) mice before and 36 h after stimulation in the presence or absence of 50 U/ml IL-2, 5 ng/ml IL-7 or both; means ± SEM of 2 mice.

(B and C) Inhibition of SOCE impairs GLUT1 expression and glucose uptake in human T cells. **(B)** GLUT1 protein expression measured by flow cytometry in CD4⁺ T cells of healthy donors (HD) 16 h after anti-CD3/CD28 stimulation in the presence or absence of 500 nM BTP-2. Representative histogram plots (left panel) and summary of 3 HD (right panel); bar graphs are means ± SEM. **(C)** Analysis of glucose uptake by HD CD4⁺ T cells 16 h after anti-CD3/CD28 stimulation in the presence or absence 500 nM BTP-2 using the fluorescent glucose analogue 2-NBDG. Representative histogram plots (left panel) and summary of 3 HD (right panel); bar graphs are means ± SEM.